Cancer Immunotherapy Biomarkers: Four Trends to Watch
- Using state of the art technologies for biomarker development
- Validating PD-L1 as a biomarker of response
- Linking tumor mutation burden to response rate
- Leveraging the tumor microenvironment to direct therapeutic development
